Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trialMehreen S. Datoo, Halidou Tinto, Karim Derra et al.|The Lancet|2021Cited by 457
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trialMehreen S. Datoo, Nsajigwa Misidai, Alassane Dicko et al.|The Lancet|2024Cited by 345
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trialMehreen S. Datoo, Halidou Tinto, Hamtandi Magloire Natama et al.|The Lancet Infectious Diseases|2022Cited by 285
Safety and efficacy of the blood-stage malaria vaccine RH5.1/Matrix-M in Burkina Faso: interim results of a double-blind, randomised, controlled, phase 2b trial in childrenHamtandi Magloire Natama, Angela M. Minassian, Jo Salkeld et al.|The Lancet Infectious Diseases|2024Cited by 39
High Efficacy of a Low Dose Candidate Malaria Vaccine, R21 in 1 Adjuvant Matrix-M™, with Seasonal Administration to Children in Burkina FasoMehreen S. Datoo, Halidou Tinto, Hamtandi Magloire Natama et al.|SSRN Electronic Journal|2021Cited by 15